U.S. health regulators on Friday approved expanding the heart benefit claims Ama...
- U.S. health regulators on Friday approved expanding the heart benefit claims Amarin Corp can make in promoting its drug Vascepa to include reducing the risk of heart attacks and strokes in high-risk patients, opening a multibillion-dollar market opportunity.
Vascepa, a highly purified form of omega-3 fatty acid, won U.S. approval in 2012 to lower high triglycerides - a type of blood fat that can increase the risk of heart disease. Vascepa has been heralded as a potential game changer in the cardiovascular disease market by Wall Street analysts. Vascepa has been highlighted as a cost-effective add-on to statins by the Institute for Clinical and Economic Review. The therapy’s annual cost based on list price of around $3,600 is much lower than the non-profit group’s recommended value-based price range of $6,300 to $9,200.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Senate confirms Dr. Stephen Hahn as FDA commissionerThe US Senate on Thursday confirmed Dr. Stephen Hahn to be the next commissioner of the US Food and Drug Administration. The Senate vote was 72 to 18.
Lire la suite »
The FDA is investigating 3 separate E. coli outbreaksJust days after health officials urged Americans to throw out their salad kits over E. coli concerns, the Food and Drug Administration announced it's investigating three separate E. coli outbreaks linked to salad products.
Lire la suite »
Senate confirms Stephen Hahn as new FDA commissionerStephen Hahn is poised to take the helm of the agency amid national concern around youth nicotine use with e-cigarettes and lung injuries connected to illicit vaping products.
Lire la suite »
U.S. FDA gives early approval to Sarepta's DMD gene therapyThe U.S. Food and Drug Administration on Thursday granted an early approval to S...
Lire la suite »
Sarepta stock surges more than 20% as FDA finally OKs muscular dystrophy drugSarepta Therapeutics Inc. shares surged in the extended session Thursday after the genetic medicine company said the Food and Drug Administration approved...
Lire la suite »